Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines worldwide. With a market cap of $10.6 billion, the company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development.

Companies valued at $10 billion or more are generally described as "large-cap stocks", and Moderna fits this criterion perfectly. The company is also expanding its pipeline to include treatments for cancer, rare diseases, and autoimmune conditions, reflecting its broader commitment to revolutionizing medicine through cutting-edge mRNA science.

Moderna currently trades 83.6% below its 52-week high of $158.82 recorded on June 6, 2024. MRNA's stock has declined 25.8% over the past three months, notably underperforming the iShares Biotechnology ETF’s (IBB) 8.6% drop.

Longer term, Moderna’s stock has fallen 37.2% on a YTD basis, whereas the IBB has decreased 5.4%. Additionally, shares of MRNA crumbled 83.1% over the past 52 weeks, significantly lagging behind the IBB’s 9.4% dip over the same period.

MRNA's stock has been trading below its 50-day and 200-day moving averages since last year, underscoring its bearish trend.

Moderna's stock soared to an all-time high of $497.49 back in August 2021, driven by increased demand for its COVID-19 vaccines. However, since then, the stock has continued to erode investors’ wealth.

Its stock fell 5.3% following the release of its mixed Q1 2025 results on May 1. The company reported revenue of $108 million, down 35.3% year-over-year, missing the Wall Street expectations of $127 million. The revenue decline was primarily due to a drop in net product sales, driven by lower vaccination rates compared to the same period last year. The bottom line came in at a loss of $2.52 per share.

Compared to its peer, Vertex Pharmaceuticals Incorporated (VRTX) has outpaced the MRNA stock. VRTX stock has soared 10.2% on a YTD basis and collapsed 8.1% over the past 52 weeks.

Among the 26 analysts covering the MRNA stock, the consensus rating is a “Hold.” Its mean price target of $52.78 suggests a staggering 102.1% upside potential from current price levels.